Trials / Completed
CompletedNCT04800237
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients With Performance Anxiety
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 230 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VQW-765 | oral capsule |
| DRUG | Placebo | oral capsule |
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2022-08-02
- Completion
- 2022-08-02
- First posted
- 2021-03-16
- Last updated
- 2024-03-20
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04800237. Inclusion in this directory is not an endorsement.